⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CUE News
Cue Biopharma, Inc.
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
globenewswire.com
JNJ
BNTX
GMAB
IMUX
INO
PDSB
AZN
GSK
MRK
BIIB
EXEL
REGN
CUE
IOBT
RAPT
PRE
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
globenewswire.com
JNJ
BNTX
CUE
GMAB
IMPP
INO
AZN
GSK
MRK
BMY
EXEL
REGN
PDSB
IOVA
RPTX
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
globenewswire.com
CUE
Form 8-K
sec.gov
CUE
Cue Biopharma Announces $50.0 Million Private Placement
globenewswire.com
CUE
Form 8-K
sec.gov
CUE
Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution
globenewswire.com
CUE
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
globenewswire.com
CUE
Form 8-K
sec.gov
CUE
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
globenewswire.com
CUE